Hospira to launch generic injectable version Bivalirudin


Hospira has announced the launch of a generic injectable version Bivalirudin for the US market. Bivalirudin is a generic version of Angiomax, which is produced by The Medicines Company. In 2014, Angiomax is estimated to have brought The Medicines Company $500 million in sales. Hospira has already successfully challenged the Angiomax patent and its generic will be the first copycat drug based on Angiomax to hit the market.


Read the source article at Pharmacy Choice

About the Author

Related Posts

Leave a Reply